Does High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance?

PLoS Computational Biology

Volumn 12, Issue 1, 2016, Pages

  Day, Troy ^a,b   Read, Andrew F ^b,c  

^a QUEEN S UNIVERSITY   (Canada)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGY; DRUG DOSAGE;

DRUG-RESISTANCE; EMPIRICAL STUDIES; EVOLUTIONARY BIOLOGY; EVOLUTIONARY PROCESS; HIGH DOSE; HIGH-DOSE CHEMOTHERAPIES; INFECTIOUS DISEASE; RELATIVE STRENGTH; RESISTANT STRAINS; UNIMODAL;

CHEMOTHERAPY;

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CELL DENSITY; CONCEPTUAL FRAMEWORK; DRUG EFFICACY; DRUG MEGADOSE; GENE MUTATION; GENOTYPE; HEPATITIS C; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MATHEMATICAL COMPUTING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT COMPLIANCE; TREATMENT DURATION; VIRUS REPLICATION; ANIMAL; BIOLOGICAL MODEL; BIOLOGY; COMMUNICABLE DISEASES; DRUG EFFECTS; DRUG RESISTANCE; EVOLUTION; MOUSE;

ANIMALS; ANTI-INFECTIVE AGENTS; BIOLOGICAL EVOLUTION; COMMUNICABLE DISEASES; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE; DRUG THERAPY; HUMANS; MICE; MODELS, BIOLOGICAL;

EID: 84956754499     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004689     Document Type: Article

References (64)

1. Ehrlich P, Chemotherapeutics: Scientific principles, methods, and results. The Lancet. 1913;182:445–451.
2. Fleming A, Penicillin. Nobel lectures, physiology or medicine 1942–1962. Elsevier Publishing Company, Amsterdam; 1964.
3. Roberts JA, Kruger P, Paterson DL, Lipman J, Antibiotic resistance: what’s dosing got to do with it? Critical Care Medicine. 2008;36:2433–2440. 18596628
4. Abdul-Aziz MH, Lipman J, Mouton JW, Hope WW, Roberts JA, Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: Optimizing efficacy and reducing resistance development. Seminars in Respiratory and Critical Care Medicine. 2015;36:136–153. doi: 10.1055/s-0034-1398490 25643277
5. Zhao X, Drlica K, Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clinical Infectious Diseases. 2001;33:S147–S156. doi: 10.1086/321841 11524712
6. Zhao X, Drlica K, Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. The Journal of Infectious Diseases. 2002;185:561–565. doi: 10.1086/338571 11865411
7. Drlica K, Zhao X, Mutant selection window hypothesis updated. Clinical Infectious Diseases. 2007;44:681–688. doi: 10.1086/511642 17278059
8. Olofsson SK, Cars O, Optimizing drug exposure to minimize selection of antibiotic resistance. Clinical Infectious Diseases. 2007;45:S129–S136. doi: 10.1086/519256 17683017
9. Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resistance Updates. 2011;14:107–117. doi: 10.1016/j.drup.2011.02.005 21440486
10. Hastings I, Why we should effectively treat malaria. Trends in Parasitology. 2011;27:51–52. doi: 10.1016/j.pt.2010.10.003 21281927
11. Canton R, Morosini MI, Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiology Reviews. 2011;35:977–991. doi: 10.1111/j.1574-6976.2011.00295.x 21722146
12. Ankomah P, Levin BR, Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections. Proceedings of the National Academy of Science. 2014;111:8331–8338. doi: 10.1073/pnas.1400352111
13. Read AF, Day T, Huijben S, The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proceedings of the National Academy of Science. 2011;108:10871–10877. doi: 10.1073/pnas.1100299108
14. Geli P, Laxminarayan R, Dunne M, Smith DL, One-Size-Fits-All? Optimizing treatment duration for bacterial infections. PLoS One. 2012;7:e29838. doi: 10.1371/journal.pone.0029838
15. Huijben S, Bell AS, Sim DG, Salathe R, Tomasello D, Mideo N, et al. Aggressive chemotherapy and the selection of drug resistant pathogens. PLoS Pathogens. 2013;9:e1003578. doi: 10.1371/journal.ppat.1003578 24068922
16. Kouyos RD, Metcalf CJE, Birger R, Klein EY, zur Wiesch PA, Ankomah P, et al. The path of least resistance: aggressive or moderate treatment? Proceedings of the Royal Society, B. 2014;281:20140566. doi: 10.1098/rspb.2014.0566
17. Schmidt LH, Walley A, Larson RD, The influence of the dosage regimen on the therapeutic activity and penicillin. Journal of Pharmacology and Experimental Therapeutics. 1949;96:258–268.
18. zur Wiesch PA, Kouyos R, Engelstader J, Regoes R, Bonhoeffer S, Population biological principles of drug-resistance evolution in infectious diseases. The Lancet, Infectious Diseases. 2011;11:236–247. doi: 10.1016/S1473-3099(10)70264-4 21371657
19. Day T, Huijben S, Read AF, Is selection relevant in the evolutionary emergence of drug resistance. Trends in Microbiology. 2015;23:126–133. doi: 10.1016/j.tim.2015.01.005 25680587
20. Coleman M, Human drug metabolism: An introduction. John Wiley and Sons, West Sussex, UK; 2010.
21. Ke R, Loverdo C, Qi H, Sun R, Lloyd-Smith JO, Rational design and adaptive management of combination therapies for Hepatitis C virus infection. PLOS Computational Biology. 2015;11:e1004040. doi: 10.1371/journal.pcbi.1004040 26125950
22. Obolski U, Hadany L, Implications of stress-induced genetic variation for minimizing multidrug resistance in bacteria. BMC Medicine. 2012;10:89. doi: 10.1186/1741-7015-10-89 22889082
23. Negri MC, Morosini MI, Loza E, Baquero F, In-vitro selective antibiotic concentrations of beta-lactams for penicillin-resistant Streptococcus-pneumoniae populations. Antimicrobial Agents and Chemotherapy. 1994;38:122–125. doi: 10.1128/AAC.38.1.122 8141563
24. Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH, In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 2003;47:1604–1613. doi: 10.1128/AAC.47.5.1604-1613.2003 12709329
25. Zinner SH, Lubenko IY, Gilbert D, Simmons K, Zhao X, Drlica K, et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model the simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. Journal of Antimicrobial Chemotherapy. 2003;52:616–622. doi: 10.1093/jac/dkg401 12951352
26. Jumbe N, Louie A, Leary R, Liu WG, Deziel MR, Tam VH, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. Journal of Clinical Investigation. 2003;112:275–285. doi: 10.1172/JCI16814 12865415
27. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL, Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. Journal of Infectious Diseases. 2004;190:1642–1651. doi: 10.1086/424849 15478070
28. Firsov AA, Vostrov SN, Lubenko IY, Arzamastsev AP, Portnoy YA, Zinner SH, ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro model. Journal of Antimicrobial Chemotherapy. 2004;54:178–186. doi: 10.1093/jac/dkh242 15190041
29. Croisier DE, M Etienne M, Bergoin E, Charles PE, Lequeu C, Piroth L, et al. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrobial Agents and Chemotherapy. 2004;48:1699–1707. doi: 10.1128/AAC.48.5.1699-1707.2004 15105123
30. Etienne M, Croisier D, Charles PE, Lequeu C, Piroth L, Portier H, et al. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits. Journal of Infectious Diseases. 2004;190:1472–1475. doi: 10.1086/423853 15378440
31. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA, Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2005;49:4920–4927. doi: 10.1128/AAC.49.12.4920-4927.2005 16304153
32. Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL, Bacterial-population responses to drug-selective pressure: examination of Garenoxacin’s effect on Pseudomonas aeruginosa. Journal of Infectious Diseases. 2005;192:420–428. doi: 10.1086/430611 15995955
33. Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH, Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro model. Journal of Antimicrobial Chemotherapy. 2006;58:1185–1192. doi: 10.1093/jac/dkl387 17028094
34. Cui JC, Liu YN, Wang R, Tong WH, Drlica K, Zhao XL, The mutant selection window in rabbits infected with Staphylococcus aureus. Journal of Infectious Diseases. 2006;194:1601–1608. doi: 10.1086/508752 17083047
35. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL, The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrobial Agents and Chemotherapy. 2007;51:744–747. doi: 10.1128/AAC.00334-06 17116679
36. Gumbo T, Louie A, Deziel MR, Liu WG, Parsons LM, Salfinger M, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrobial Agents and Chemotherapy. 2007;51:3781–3788. doi: 10.1128/AAC.01533-06 17724157
37. Bourgeois-Nicolaos N, Massias L, Couson B, Butel MJ, Andremont A, Doucet-Populaire F, Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo. Journal of Infectious Diseases. 2007;195:1480–1488. doi: 10.1086/513876 17436228
38. Goessens WHE, Mouton JW, ten Kate MT, Bijll AJ, Ott A, Bakker-Woudenberg I, Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection. Journal of Antimicrobial Chemotherapy. 2007;59:507–516. doi: 10.1093/jac/dkl529 17289765
39. Stearne LET, Goessens WHF, OlofssonCars JW, Gyssens IC, Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection. Antimicrobial Agents and Chemotherapy. 2007;51:3605–3611. doi: 10.1128/AAC.01486-06 17646416
40. Zhu YL, Mei Q, Cheng J, Liu YY, Ye Y, Li JB, Testing the mutant selection window in rabbits infected with methicillin-resistant Staphylococcus aureus exposed to vancomycin. Journal of Antimicrobial Chemotherapy. 2012;67:2700–2706. doi: 10.1093/jac/dks280 22809703
41. Schmalstieg AM, Srivastava S, Belkaya S, Deshpande D, Meek C, Leff R, et al. The antibiotic resistance arrow of time: Efflux pump induction is a general first step in the evolution of Mycobacterial drug resistance. Antimicrobial Agents and Chemotherapy. 2012;56:4806–4815. doi: 10.1128/AAC.05546-11 22751536
42. Fantin B, Farinotti R, Thabaut A, Carbon C, Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 1994;33:563–569. doi: 10.1093/jac/33.3.563 8040120
43. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrobial Agents and Chemotherapy. 1998;42:521–527. 9517926
44. Negri MC, Lipsitch M, Blazquez J, Levin BR, Baquero F, Concentration-dependent selection of small phenotypic differences in TEM β-lactamase-mediated antibiotic resistance. Antimicrobial Agents and Chemotherapy. 2000;44:2485–2491. doi: 10.1128/AAC.44.9.2485-2491.2000 10952599
45. Wiuff C, Lykkesfeldt J, Svendsen O, Aarestrup FM, The effects of oral and intramuscular administration and dose escalation of enrofloxacin on the selection of quinolone resistance among Salmonella and coliforms in pigs. Research in Veterinary Science. 2003;75:185–193. doi: 10.1016/S0034-5288(03)00112-7 13129666
46. Wargo AR, Huijben S, de Roode JC, Shepherd J, Read AF, Competitive release and facilitation of drug resistant parasites following therapeutic chemotherapy in a rodent malaria model. Proceedings of the National Academy of Sciences. 2007;104:19914–19919. doi: 10.1073/pnas.0707766104
47. Huijben S, Nelson WA, Wargo AR, Sim DG, Drew DR, Read AF, Chemotherapy, within-host ecology and the fitness of drug resistant malaria parasites. Evolution. 2010;64:2952–2968. doi: 10.1111/j.1558-5646.2010.01068.x 20584075
48. Gullberg E, Cao S, Berg OG, Ilback C, Sandergren L, Hughes D, et al. Selection of resistant bacteria a very low antibiotic concentrations. PLOS Pathogens. 2011;7:e1002158. doi: 10.1371/journal.ppat.1002158 21811410
49. Nguyen TT, Chachaty E, Huy C, Cambier C, de Gunzburg J, Mentre F, et al. Correlation between fecal concentrations of ciprofloxacin and fecal counts of resistant Enterobacteriaceae in piglets treated with ciprofloxacin: Toward new means to control the spread of resistance? Antimicrobial Agents and Chemotherapy. 2012;56:4973–4975. doi: 10.1128/AAC.06402-11 22751547
50. Pollitt LC, Huijben S, Sim DG, Salathe RM, Jones MJ, Read AF, Rapid response to selection, competitive release and increased transmission potential of artesunate-selected Plasmodium chabaudi malaria parasites. PLoS Pathogens. 2014;10:e1004019. doi: 10.1371/journal.ppat.1004019
51. Vasseur MV, Laurentie M, Rolland JG, Perrin-Guyomard A, Henri J, Ferran AA, et al. Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora. Antimicrobial Agents and Chemotherapy. 2014;58:1744–1748. doi: 10.1128/AAC.02135-13 24395228
52. Zhao X, Clarification of MPC and the mutant selection window concept. Journal of Antimicrobial Chemotherapy. 2003;52:731. doi: 10.1093/jac/dkg376 12972446
53. Firsov AA, Golikova MV, Strukova EN, Portnoy YA, Romanov AV, Edelstein MV, et al. In vitro resistance studies with bacteria that exhibit low mutation frequencies: Prediction of “antimutant” linezolid concentrations using a mixed inoculum containing both susceptible and sesistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 2015;59:1014–1019. doi: 10.1128/AAC.04214-14 25451050
54. Smith HJ, Nichol KA, Hoban DJ, Zhanel GG, Stretching the mutant prevention concentration (MPC) beyond its limits. Journal of Antimicrobial Chemotherapy. 2003;51:1323–1325. doi: 10.1093/jac/dkg255 12716780
55. Dong YZ, Zhao XL, Kreiswirth BN, Drlica K, Mutant prevention concentration as a measure of antibiotic potency: Studies with clinical isolates of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2000;44:2581–2584. doi: 10.1128/AAC.44.9.2581-2584.2000 10952625
56. Livermore DM, Overstretching the mutant prevention concentration. Journal of Antimicrobial Chemotherapy. 2003;52:732. doi: 10.1093/jac/dkg377 12972447
57. Modi SR, Collins JJ, Relman DA, Antibiotics and gut microbiota. Journal of Clinical Investigation. 2015;124:4212. doi: 10.1172/JCI72333
58. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults—A randomized trial. Journal of the American Medical Association. 2003;290:2588–2598. doi: 10.1001/jama.290.19.2588 14625336
59. Basoli A, Chirletti P, Cirino E, D’Ovidio NG, Doglietto GB, Giglio D, et al. A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs > = 5 days in community-acquired intraabdominal infection. Journal of Gastrointestinal Surgery. 2008;12:592–600. doi: 10.1007/s11605-007-0277-x 17846853
60. Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of short-course antimicrobial therapy for intraabdominal Infection. New England Journal of Medicine. 2015;372:1996–2005. doi: 10.1056/NEJMoa1411162 25992746
61. Rice LB, The Maxwell Finland lecture: For the duration—Rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile. Clinical Infectious Diseases. 2008;46:491–496. doi: 10.1086/526535 18194098
62. Aliberti S, Giuliani F, Ramirez J, Blasi F, Grp DS, How to choose the duration of antibiotic therapy in patients with pneumonia. Current Opinion in Infectious Diseases. 2015;28:177–184.25692271
63. van den Bosch F, Paveley N, Shaw M, Hobbelen P, Oliver R, The dose rate debate: does the risk of fungicide resistance increase or decrease with dose? Plant Pathology. 2011;60:597–606. doi: 10.1111/j.1365-3059.2011.02439.x
64. Gatenby RA, A change of strategy in the war on cancer. Nature. 2009;459:508–509. doi: 10.1038/459508a 19478766